Ingrid Garajová
YOU?
Author Swipe
View article: Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab
Statins and clinical outcomes in patients with advanced hepatocellular carcinoma treated with Atezolizumab plus Bevacizumab Open
The impact of statins on patients receiving immune checkpoint inhibitors for advanced hepatocellular carcinoma (aHCC) remains unclear. This study aimed to evaluate whether statins influence overall survival (OS) and progression-free surviv…
View article: Perineural Invasion in Pancreatic Ductal Adenocarcinoma: Recapitulating Its Importance and Defining Future Directions
Perineural Invasion in Pancreatic Ductal Adenocarcinoma: Recapitulating Its Importance and Defining Future Directions Open
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most lethal malignancies, mainly due to its aggressive nature, early metastasis, diagnosis at late stages, and limited response to systemic anticancer therapy. Perineural invasion …
View article: Negative impact of corticosteroid use on outcome in patients with advanced <scp>BTCs</scp> treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population
Negative impact of corticosteroid use on outcome in patients with advanced <span>BTCs</span> treated with cisplatin, gemcitabine, and durvalumab: A large real‐life worldwide population Open
In recent years, there has been increasing interest in the possible prognostic impact of concomitant medications in patients with cancer treated with immunotherapy combinations. This real‐world analysis aims to evaluate the impact of conco…
View article: Navigating the paradox of senescence and chemoresistance in pancreatic cancer
Navigating the paradox of senescence and chemoresistance in pancreatic cancer Open
Cellular senescence, described as a mechanism of irreversible cell cycle arrest, has emerged as a complex and multifaceted process with significant implications in cancer biology, particularly in pancreatic ductal adenocarcinoma (PDAC). Th…
View article: Etiology of hepatocellular carcinoma may influence the pattern of progression under atezolizumab-bevacizumab.
Etiology of hepatocellular carcinoma may influence the pattern of progression under atezolizumab-bevacizumab. Open
Background: Preclinical models have shown that metabolic dysfunction-associated steatotic liver disease (MASLD)-related hepatocellular carcinoma (HCC) may exhibit reduced responsiveness to immunotherapy, especially for intrahepatic lesions…
View article: Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study Open
Standard of care first‐line systemic treatment for advanced biliary tract cancer includes chemo‐immunotherapy with gemcitabine, cisplatin, and durvalumab, followed by maintenance durvalumab monotherapy. The present work aims to investigate…
View article: Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline <scp><i>BRCA</i>1</scp>‐2 Pathogenic Variants
Real‐World Impact of Olaparib Exposure in Advanced Pancreatic Cancer Patients Harboring Germline <span><i>BRCA</i>1</span>‐2 Pathogenic Variants Open
Introduction Pancreatic cancer arising in the context of BRCA predisposition may benefit from poly(ADP‐ribose) polymerase inhibitors. We analyzed real‐world data on the impact of olaparib on survival in metastatic pancreatic cancer patient…
View article: Targeting Perineural Invasion in Pancreatic Cancer
Targeting Perineural Invasion in Pancreatic Cancer Open
Pancreatic cancer is an aggressive tumor with dismal prognosis. Neural invasion is one of the pathological hallmarks of pancreatic cancer. Peripheral nerves can modulate the phenotype and behavior of the malignant cells, as well as of diff…
View article: NGF-mediated crosstalk: unraveling the influence of metabolic deregulation on the interplay between neural and pancreatic cancer cells and its impact on patient outcomes
NGF-mediated crosstalk: unraveling the influence of metabolic deregulation on the interplay between neural and pancreatic cancer cells and its impact on patient outcomes Open
Neural invasion is one of the most common routes of invasion in pancreatic cancer and it is responsible for the high rate of tumor recurrence after surgery and the pain generation associated with pancreatic cancer. Several molecules implic…
View article: Spontaneous Regression of an Inflammatory Myofibroblastic Tumor: A Case Report and a Review of the Literature
Spontaneous Regression of an Inflammatory Myofibroblastic Tumor: A Case Report and a Review of the Literature Open
Introduction: Spontaneous tumor regression is the volumetric reduction or complete disappearance of a primary tumor or metastatic sites (single or multiple) without the administration of treatments. This rare phenomenon occurs most commonl…
View article: Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population Open
Background In the TOPAZ-1, patients with biliary tract cancers (BTC) and recurrence within 6 months after surgery were excluded, even if this event is frequently observed in clinical practice. Our study aimed to assess if the efficacy of c…
View article: Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma
Suboptimal outcomes of sorafenib as a second-line treatment after atezolizumab-bevacizumab for unresectable hepatocellular carcinoma Open
In patients progressing under AB, the efficacy of sorafenib on different outcomes is limited.
View article: Focus on Pancreatic Cancer Microenvironment
Focus on Pancreatic Cancer Microenvironment Open
Pancreatic ductal adenocarcinoma remains one of the most lethal solid tumors due to its local aggressiveness and metastatic potential, with a 5-year survival rate of only 13%. A robust connection between pancreatic cancer microenvironment …
View article: Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer
Plasma miR-379 can predict treatment response to FOLFIRINOX and gemcitabine-nab-paclitaxel in advanced pancreatic cancer Open
Plasma miR-379 appears clinically useful as a predictive biomarker to identify which patients with advanced PDAC benefit most from treatment with FOLFIRINOX or gemcitabine-nab-paclitaxel. Further validation in larger studies and clinical t…
View article: Unraveling the Connection: Pancreatic Cancer Cells and Schwann Cells
Unraveling the Connection: Pancreatic Cancer Cells and Schwann Cells Open
Pancreatic ductal adenocarcinoma is one of the most lethal solid malignancies, characterized by its aggressiveness and metastatic potential, with a 5-year survival rate of only 13%. Progress in the management of metastatic disease has been…
View article: Advances in the management of hepatobiliary and pancreatic malignancies: highlights from the ESMO Annual Meeting 2023 by the EORTC GI Tract Cancer Group
Advances in the management of hepatobiliary and pancreatic malignancies: highlights from the ESMO Annual Meeting 2023 by the EORTC GI Tract Cancer Group Open
International audience
View article: Association of hypothyroidism with survival in pancreatic cancer: retrospective cohort study
Association of hypothyroidism with survival in pancreatic cancer: retrospective cohort study Open
Pancreatic ductal adenocarcinoma (PDAC) remains one of the most aggressive tumours, with a 5-year survival rate of approximately 8 per cent. This is mostly due to the delay in early diagnosis and to tumour resistance against treatments, de…
View article: ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells
ABCB1 overexpression through locus amplification represents an actionable target to combat paclitaxel resistance in pancreatic cancer cells Open
Background Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of cancer and the chemotherapies such as gemcitabine/nab-paclitaxel are confronted with intrinsic or acquired resistance. The aim of this study was to investi…
View article: Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain?
Second-Line Chemotherapy for Intrahepatic Cholangiocarcinomas: What Is the Real Gain? Open
Background: The presence of actionable alterations in advanced biliary tract cancer patients opened new therapeutic possibilities for second-line treatments. However, for around 60% of the patients, chemotherapy remains the only therapeuti…
View article: A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists
A Simple Overview of Pancreatic Cancer Treatment for Clinical Oncologists Open
Pancreatic cancer (PDAC) is one of the most aggressive solid tumors and is showing increasing incidence. The aim of our review is to provide practical help for all clinical oncologists and to summarize the current management of PDAC using …
View article: Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers
Prediction Model for Early-Stage Pancreatic Cancer Using Routinely Measured Blood Biomarkers Open
Importance Accurate risk prediction models using routinely measured biomarkers—eg, carbohydrate antigen 19-9 (CA19-9) and bilirubin serum levels—for pancreatic cancer could facilitate early detection of pancreatic cancer and prevent potent…